ARTICLE | Company News

Applied Microbiology deal

March 7, 1994 8:00 AM UTC

AMBI (New York) and Merck & Co.'s Astra/Merck Group will develop products to eliminate Helicobacter pylori, a bacterium associated with the development of most peptic ulcers. Astra/Merck received exclusive licenses to AMBI's antimicrobial peptides in pharmaceutical products to eliminate H. pylori. The deal includes royalty payments to AMBI. ...